Deyaa Adib, MD, on Targeting HER2 in Solid Tumors With the TAC Platform
The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.
Peter Bross, MD, on the Importance of Transparency and Communication With the FDA
The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
Deyaa Adib, MD, on Using T-Cell Antigen Coupler Technology to Target Solid Tumors
The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.
Pursuing Strategic Partnerships in Cell Therapy
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.
Stephanie Cherqui, PhD, on Bringing Attention to Cystinosis and Gene Therapy
The associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.
Geoffrey Hodge on Developing CAR T-Cell Therapies for Solid Tumors
Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
Susan Ruediger on Pursuing Gene Therapies for CMT
Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the foundation’s mission.
Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell Development
The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
Freeline Moves Closer to Identifying Hemophilia B Gene Therapy Dose
A second cohort has been dosed with 7.7e11 vg/kg to hopefully confirm the dose for phase 3 trials.
Gavin Macbeath, PhD, on Screening for Off-Target Effects
The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.
Michael Leek, PhD, on Manufacturing Challenges in Cell Therapy
The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
Serena De Vita, MD, PhD, on Speedy Manufacturing of PHE885 for Multiple Myeloma
The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
Jeffrey Miller, MD, on Improving NK Cells for Solid and Hematologic Malignancies
The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.
Stefanie Bailey, PhD, on the Role of Interferon-γ in CAR T-Cell Therapy
The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.
Adham Bear, MD, On Immunotherapy Targeting Mutant KRAS
The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
Mazyar Shadman, MD, MPH, on MB-106's Potential in Follicular Lymphoma
The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.
Christian Hinrichs, MD, on Improving Solid Tumor Targeting With Engineered T-Cell Therapies
The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.
Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells
The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
Peter Bross, MD, on Regulating Cell Therapies: Lessons Learned
The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.
Connecting Patient Advocacy and Industry for Gene Therapy Development
Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the panel discussion she participated in at BIO 2022.
T-Charge CAR T-Cell Therapy Shows Efficacy in Multiple Myeloma
The therapy is now being evaluated in a phase 2 study.
CTX130 Shows Acceptable Safety Profile, Clinically Meaningful Responses in R/R T-Cell Lymphoma
CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).
Frederick Locke, MD, on Further CAR T Research
The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed more work to be done with CAR T-cell therapies.
CAR T-Cell Therapy Yields High Response Rates in Follicular Lymphoma
Mustang Bio presented data on MB-106 at the 2022 EHA Congress.
Tisa-Cel Shows Durable Efficacy in Pediatric and Young Adult Patients With R/R B-Cell Acute Lymphoblastic Leukemia
Among treated patients, 42% achieved 5-year event free survival.
Re-Dosing With Gene Therapies in Rare Diseases
Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.
Dual-Targeted CAR T-Cell Therapy Continues to Show Efficacy in R/R Multiple Myeloma
GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.
Anbal-Cel Shows Promising Responses in Large B-Cell Lymphoma
The CD-19 CAR T-cell therapy is developed using Curocell’s OVISTM platform.
Exa-Cel Eliminates Transfusions in TD Thalassemia and VOCs in Sickle Cell Disease
Results from the CLIMB THAL-111 and CLIMB SCD-121 trials were presented at the EHA 2022 Congress.
Axi-Cel More Efficacious With Higher Toxicity Than Tisa-Cel in Diffuse Large B-Cell Lymphoma
Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.
